View Entire Collection
By Clinical Topic
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
TUESDAY, July 26 (HealthDay News) -- Treatment with propranolol reduces the volume, color, and elevation of infantile hemangiomas (IHs), according to a study published online July 25 in Pediatrics.
Marcia Hogeling, M.D., from the Sydney Children's Hospital in Australia, and colleagues assessed the safety and efficacy of propranolol hydrochloride for treating IHs. A cohort of 40 children, aged 9 weeks to 5 years, with facial IHs and IHs in other sites with potential for disfigurement was randomized to receive an oral solution of 2 mg/kg per day propranolol or placebo for six months. The efficacy of treatment was measured every four weeks up to six months, and photographs were scored at 0, 12, and 24 weeks.
The investigators found that, in the propranolol group, IH growth stopped by week four. The percentage change in volume was significantly different between the two groups, with the largest difference seen at week 12. IH redness and elevation were significantly reduced in the propranolol group at weeks 12 and 24. No cases of significant hypoglycemia, hypotension, or bradycardia were seen. There was one drop out due to an upper respiratory infection. Other adverse events included bronchiolitis, gastroenteritis, streptococcal infection, cool extremities, dental caries, and sleep disturbance.
"This randomized controlled trial revealed that propranolol is a safe and effective medication for treating IHs," the authors write.
Full Text (subscription or payment may be required)
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top